Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Apr 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of imaging called CAIX-targeted PET imaging to see how well it can help diagnose and stage kidney cancer. The goal is to find out if this imaging method can provide important information about the cancer's progression and how effective the treatment is. If you or a loved one has been diagnosed with kidney cancer, particularly types like clear cell carcinoma, papillary renal cell carcinoma, or chromophobe renal cell carcinoma, you may be eligible to participate in this study.

To join, participants need to be between 18 and 75 years old, agree to sign a consent form, and have had a recent enhanced CT scan. The study is currently recruiting, so there are opportunities to get involved. Participants can expect to undergo the CAIX-targeted PET imaging, which is a non-invasive procedure, and will need to attend follow-up visits to monitor their health and treatment. It’s important to note that pregnant or breastfeeding individuals cannot participate, and those with certain health issues may not qualify. This trial could provide valuable insights into kidney cancer and contribute to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntary participation with the patient or their legal representative able to sign the informed consent form.
• • 2. Adult patients (age between 18 and 75 years), regardless of gender.
• • 3. Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).
• • 4. Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.
• • 5. ECOG performance status score of 0-3.
• 6. Laboratory parameters must meet the following criteria:
• • 1. ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.
• • 2. Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L.
• • 7. Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).
• • 2. Patients or their legal representatives who are unable or unwilling to sign the informed consent form.
• • 3. Acute systemic diseases and electrolyte imbalances.
• • 4. Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).
• • 5. Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.